These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19787792)

  • 1. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.
    Ottaviano L; Schaefer KL; Gajewski M; Huckenbeck W; Baldus S; Rogel U; Mackintosh C; de Alava E; Myklebost O; Kresse SH; Meza-Zepeda LA; Serra M; Cleton-Jansen AM; Hogendoorn PC; Buerger H; Aigner T; Gabbert HE; Poremba C
    Genes Chromosomes Cancer; 2010 Jan; 49(1):40-51. PubMed ID: 19787792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
    Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
    Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
    Zheng L; Wang F; Qian C; Neumann RM; Cheville JC; Tindall DJ; Liu W
    Hum Mutat; 2006 Oct; 27(10):1062-3. PubMed ID: 16941491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
    Markl ID; Jones PA
    Cancer Res; 1998 Dec; 58(23):5348-53. PubMed ID: 9850064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.
    Greenblatt MS; Beaudet JG; Gump JR; Godin KS; Trombley L; Koh J; Bond JP
    Oncogene; 2003 Feb; 22(8):1150-63. PubMed ID: 12606942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
    Havrilesky LJ; Alvarez AA; Whitaker RS; Marks JR; Berchuck A
    Gynecol Oncol; 2001 Dec; 83(3):491-500. PubMed ID: 11733961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.
    Sartor M; Steingrimsdottir H; Elamin F; Gäken J; Warnakulasuriya S; Partridge M; Thakker N; Johnson NW; Tavassoli M
    Br J Cancer; 1999 Apr; 80(1-2):79-86. PubMed ID: 10389982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.
    Geradts J; Kratzke RA; Niehans GA; Lincoln CE
    Cancer Res; 1995 Dec; 55(24):6006-11. PubMed ID: 8521382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
    Sanchez-Cespedes M; Reed AL; Buta M; Wu L; Westra WH; Herman JG; Yang SC; Jen J; Sidransky D
    Oncogene; 1999 Oct; 18(43):5843-9. PubMed ID: 10557071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
    Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
    Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.
    Bloethner S; Hemminki K; Thirumaran RK; Chen B; Mueller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
    Melanoma Res; 2006 Aug; 16(4):297-307. PubMed ID: 16845325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA; Lupu R
    Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
    Elisei R; Shiohara M; Koeffler HP; Fagin JA
    Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
    Liu Y; Bodmer WF
    Proc Natl Acad Sci U S A; 2006 Jan; 103(4):976-81. PubMed ID: 16418264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
    Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
    Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular analysis of the Ink4a/Rb1-Arf/Tp53 pathways in radon-induced rat lung tumors.
    Bastide K; Guilly MN; Bernaudin JF; Joubert C; Lectard B; Levalois C; Malfoy B; Chevillard S
    Lung Cancer; 2009 Mar; 63(3):348-53. PubMed ID: 18656278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of 4 new human pancreatic cancer cell lines: evidences of different tumor phenotypes.
    Chifenti B; Morelli M; Zavaglia M; Coviello DA; Guerneri S; Santucci A; Paffetti A; Masetti M; Locci MT; Bertacca G; Capodanno A; Collecchi P; Campani D; Mosca F; Bevilacqua G; Cavazzana AO
    Pancreas; 2009 Mar; 38(2):184-96. PubMed ID: 19002021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).
    de vos tot Nederveen Cappel WH; Offerhaus GJ; van Puijenbroek M; Caspers E; Gruis NA; De Snoo FA; Lamers CB; Griffioen G; Bergman W; Vasen HF; Morreau H
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3598-605. PubMed ID: 14506146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.